Navigation Links
RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
Date:2/8/2013

r 1000 male to 2.8 per 1000 female children, averaged at 3.2 per 1000 children, which is expected to increase due to reduction of premature death.

In the clinical study investigators employ a variety of methods to assess efficacy: K-ABC: Kaufman Assessment Battery for Children, Gross Motor Function Measure, (GMFM), box and block test, Modified Asworth Scale, MAS, finger tapping test, Brain SPECT and MRI.

Dr. JC Ra, president of RNL BIO Stem Cell Technology Institute, said, "It is our mission to find cures for incurable diseases, such as the terrible pediatric curse of cerebral palsy, through autologous stem cell technology." 

About RNL BIO

RNL BIO is a premier biotechnology company focused on the research and development of adult derived stem cell technologies. RNL has completed one phase I trial for spinal cord injury and one Phase II clinical trial for Osteoarthritis and is near to the completion of Buerger's Disease trial. RNL has been a supporter of UN Global Compact's free program to work with children who suffer from cerebral palsy, as major sponsor of the Bethesda Life Foundation. RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.


'/>"/>
SOURCE RNL BIO
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
2. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
3. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
4. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
5. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
6. Lotus Pharmaceutical Company Inc. Filed Its Abbreviated New Drug Application (ANDA) Containing a Paragraph IV Certification for a Generic Version of Xenical(R) with the U.S. Food & Drug Administration (FDA)
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 In accordance with Rule 17.1 and Rule ... the United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty ... Corporation (NYSE: ELN). Background On 2 ... offer for the entire of the issued and to be ... Offer").  On 20 May 2013, Royalty Pharma ...
(Date:5/23/2013)... WASHINGTON , May 23, 2013  Vanda Pharmaceuticals Inc. ... company has been named the 2013 Life Science Firm of ... (TCM).  Vanda was honored at the TCM,s 25 ... Bethesda , Maryland.  The Tech Awards Celebration recognizes the ... in Maryland and the surrounding regions. ...
(Date:5/23/2013)... 2013 Nephros, Inc. (OTC Bulletin Board: ... that develops and sells high performance liquid purification ultrafilters, ... In addition, the concurrent temporary reduction in exercise price ... 17, 2013. Nephros estimates that it will ... offering.   A portion of the proceeds will be used ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... Pharmaceuticals, Inc. (NASDAQ: OPTR ) announced today ... antibiotics in two Phase 3 clinical trials exploring the ... adult patients with Clostridium difficile -associated diarrhea (CDAD) ... Clinical Infectious Diseases (CID). The analysis found ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... CMED ), a leading China-based advanced ... unaudited financial results for the first ... ("1Q FY2011") today.1 Q FY20 ...
Cached Medicine Technology:Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 2Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 3Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 4Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 5Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 6China Medical Technologies Reports First Fiscal Quarter Financial Results 2China Medical Technologies Reports First Fiscal Quarter Financial Results 3China Medical Technologies Reports First Fiscal Quarter Financial Results 4China Medical Technologies Reports First Fiscal Quarter Financial Results 5China Medical Technologies Reports First Fiscal Quarter Financial Results 6China Medical Technologies Reports First Fiscal Quarter Financial Results 7China Medical Technologies Reports First Fiscal Quarter Financial Results 8China Medical Technologies Reports First Fiscal Quarter Financial Results 9China Medical Technologies Reports First Fiscal Quarter Financial Results 10China Medical Technologies Reports First Fiscal Quarter Financial Results 11China Medical Technologies Reports First Fiscal Quarter Financial Results 12China Medical Technologies Reports First Fiscal Quarter Financial Results 13China Medical Technologies Reports First Fiscal Quarter Financial Results 14China Medical Technologies Reports First Fiscal Quarter Financial Results 15China Medical Technologies Reports First Fiscal Quarter Financial Results 16China Medical Technologies Reports First Fiscal Quarter Financial Results 17China Medical Technologies Reports First Fiscal Quarter Financial Results 18China Medical Technologies Reports First Fiscal Quarter Financial Results 19
(Date:5/24/2013)... KC and Monica Craichy, Founders of ... Their oldest sons, Kyle and Austin Craichy, will be kiteboarding ... several professional kiteboarders. , KC Craichy said he is excited ... come together such that virtually everyone who planned to be ... kite boarders will meet at Matheson Hammock Park and Beach ...
(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group ... more than 59,229 complaints since 2004 from women claiming they ... known as the Mirena IUD.* , Among the most common ... ‘expulsion,’ where the IUD came out on its own. There ... News article. “Abdominal pain is also common, with 3,774 complaints. ...
(Date:5/24/2013)... Denver, CO (PRWEB) May 24, 2013 ... SEO analysis, in partnership with JD Media Surge, a ... , The dental SEO analysis service will focus ... high in the search engines for their competitive keywords. ... the dentists website and recommendations based on what their ...
(Date:5/24/2013)... 24, 2013 Gift Card Network ... competitors in sustainable card material, are combining forces ... materials as a sustainable gift card substrate. , ... industry challenges and increase education and usage of ... support the reduction of carbon footprint and environmental ...
(Date:5/24/2013)... 24, 2013 Started in 1982, AMTC’s SHINE ... Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is a ministry ... supermodel Millie Lewis and her daughter, Carey Lewis Arban. , ... casting directors, and music professionals including the New York Film ... Media. They are kings of Hollywood and Christian casting directors. ...
Breaking Medicine News(10 mins):Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2
... studies that was presented yesterday at Digestive Disease Week? ... compounds can sustain relief for these patients with symptoms ... to review the therapeutic benefits for irritable bowel syndrome ... of the bowel disorders like IBS and Crohn's disease ...
... surgeon Dr Jerome Blanchard who had removed the wrong kidney ... , ,The disciplinary hearing was told yesterday that ... a patient and left her dependent on dialysis, as he ... Blanchard took out his patient’s transplant kidney, which was still ...
... says that each time an elderly person falls at ... two days of crew time.// ,Significant numbers ... suggesting that these facilities are relying on ambulance services ... calls for falls made to the ambulance service in ...
... on 100 soft drinks and beverages by the FDA (Food ... the presence of benzene//, a carcinogen in much higher amount ... ,FDA had alerted these companies, and they had ... done so. Though environmental companies had expressed concern regarding this, ...
... facility for the Medical Linear Accelerator (LINAC) here under ... (DIT). ,The Society for Applied Microwave Electronics ... which pioneered the development of an indigenous Medical LINAC, ... a cost of Rs 24.88 crore, DIT Secretary D ...
... such as gastric bypass and laparoscopic reflux ... reflux// disease respectively, are becoming popular, highlights ... Week, which represents the largest gathering of ... such as gastroenterology, endoscopy, gastrointestinal surgery and ...
Cached Medicine News:Health News:New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders 2Health News:New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders 3Health News:Consultant Bungles A Kidney Surgery 2Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 2Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 3Health News:Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity 2Health News:Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: